Last 0.12 GBp
Change Today -0.005 / -4.17%
Volume 2.1M
PYC On Other Exchanges
Symbol
Exchange
London
As of 11:31 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

physiomics plc (PYC) Snapshot

Open
0.12 GBp
Previous Close
0.12 GBp
Day High
0.12 GBp
Day Low
0.12 GBp
52 Week High
08/14/14 - 0.25 GBp
52 Week Low
11/19/14 - 0.12 GBp
Market Cap
2.3M
Average Volume 10 Days
3.1M
EPS TTM
-0.0002 GBp
Shares Outstanding
2.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHYSIOMICS PLC (PYC)

Related News

No related news articles were found.

physiomics plc (PYC) Related Businessweek News

No Related Businessweek News Found

physiomics plc (PYC) Details

Physiomics Plc provides outsourced systems and computational biology services to pharmaceutical companies in the United Kingdom, the United States, and European Union. The company’s services include Virtual Tumour, which is used to optimize the dosing and scheduling of oncology drugs in pre-clinical trials; and Virtual Tumour Preclinical that provides a rationale for designing a schedule, and allows to prioritize the drug combinations; and services to predict cardiac toxicity. It also offers model based drug development services, including population PKPD analysis of clinical data, back-translational analysis, optimal design of future studies, and preparation for due diligence. In addition, the company offers target validation and lead selection services. Further, it is developing Virtual Tumor Clinical to predict optimal regimens for human clinical trials; cardiac tox prediction service to predict unwanted toxic side effects of drug candidates early on in the drug discovery process; and drug combinations database for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. The company has collaboration and partnership agreements with Eli Lilly, Sareum, Institute of Cancer Research, Cancer Research Technology, Cyclacel Pharmaceutical, ValiRx, Phramacometrics, Institute of Life Science at Swansea University, TEMPO, and Bayer Technology Services GmbH. Physiomics Plc is based in Oxford, the United Kingdom.

5 Employees
Last Reported Date: 11/20/14

physiomics plc (PYC) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 108.6K GBP
Chief Operating Officer, Director and Member ...
Total Annual Compensation: 58.5K GBP
Compensation as of Fiscal Year 2014.

physiomics plc (PYC) Key Developments

Physiomics plc Reports Final Earnings Results for the Year Ended June 30, 2014

Physiomics plc reported final earnings results for the year ended June 30, 2014. For the year, the company reported revenue of £267,903 compared to £240,000 a year ago. Operating loss was £465,265 compared to £548,342 a year ago. Loss before taxation was £464,252 compared to £543,791 a year ago. Loss for the year attributable to equity shareholders was £425,621 or 0.026 pence per basic and diluted share compared to £500,571 or 0.033 pence per basic and diluted for the last year. Net cash used in operating activities was £351,507 compared to £524,487 a year ago. Purchase of non-current assets, net of grants received was £2,597 compared to £1,852 for the last year.

Physiomics plc, Annual General Meeting, Dec 15, 2014

Physiomics plc, Annual General Meeting, Dec 15, 2014., at 11:00 GMT Standard Time. Location: Taylor Vinters LLP, Tower 42.

Physiomics plc Launches Predictive Web-Based Platform for Cardiac Toxicity

Physiomics plc has launched its predictive web-based platform for cardiac toxicity. EasyAP™ provides cardiac action potential time course simulations to facilitate the prediction of cardiac toxicity and compound selection. Cardiac toxicity is a cause of attrition in clinical studies and post-marketing withdrawal. As an FDA requirement, all candidate drugs must be screened for activity against the hERG potassium channel. However, measurement of hERG activity is not sufficient to accurately predict cardiac toxicity. Physiomics' EasyAP™ takes into account activity against hERG and two additional ion channels to deliver action potential time courses and duration calculations based on several literature models. This platform will allow a wider access to Physiomics existing cardiac toxicity prediction service. This will enable customers to access results immediately and significantly cut the time taken by Physiomics staff to perform such studies. To allow access to the service to a broad range of customers, the platform will allow customers to run simulations on their own computers on a "pay-as-you-go" or a subscription basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PYC:LN 0.12 GBp -0.005

PYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PYC.
View Industry Companies
 

Industry Analysis

PYC

Industry Average

Valuation PYC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 15.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHYSIOMICS PLC, please visit www.physiomics-plc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.